Home Patent Forecast® Sectors Log In   Sign Up   Free Trial   Support   Contact   Pricing  
How it works Patent Forecast® Sectors Pricing Insights
Menu
Enjoy your FREE PREVIEW which shows only 2020 data and 25 documents. For full access, try it free at any time.        

Cannabis: Compositions

Search All Applications in Cannabis: Compositions


Application US20190160023


Published 2019-05-30

Use Of Cannabidivarin In The Treatment Of Autism Spectrum Disorder, Associated Disorders And Schizophrenia

The present invention relates to the use of cannabidivarin (CBDV) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS). In a further embodiment the invention relates to the use of CBDV in the treatment of schizophrenia. CBDV has been shown to be particularly effective in improving cognitive dysfunction in rodent models of ASD, FXS, RS, AS and schizophrenia. The CBDV is preferably substantially pure. It may take the form of a highly purified extract of cannabis such that the CBDV is present at greater than 95% of the total extract (w/w) and the other components of the extract are characterised. Alternatively, the CBDV is synthetically produced.


Classification


Much More than Average Length Specification


View the Patent Matrix® Diagram to Explore the Claim Relationships

USPTO Full Text Publication >

5 Independent Claims

  • Independent Claim 1. A method of treating one or more symptoms or disease characteristics associated with autistic spectrum disorder (ASD) or ASD-associated disorders, as defined by DSM-IV, in a subject in need thereof, the method comprising administering cannabidivarin to the subject, wherein the one or more symptoms or disease characteristics are one or more of: (i) qualitative impairment in social interaction(ii) qualitative impairment in communicationand (iii) restricted repetitive and stereotyped patterns of behaviour interest and activities.

  • Independent Claim 6. A method of treating one or more symptoms or disease characteristics associated with autistic spectrum disorder (ASD) or ASD-associated disorders, as defined by DSM-V, in a subject in need thereof, the method comprising administering cannabidivarin to the subject, wherein the one or more symptoms or disease characteristics are one or more of: (a) persistent deficits in social communication and social interaction across contexts, not accounted for by general developmental delays, and (b) restricted, repetitive patterns of behaviour, interests, or activities.

  • Independent Claim 13. -32. (canceled)

  • Independent Claim 33. A method of treating schizophrenia in a subject in need thereof, comprising administering an effective amount of cannabidivarin (CBDV) to the subject.

  • Independent Claim 34. A method of treating cognitive dysfunction in a subject in need thereof, comprising administering an effective amount of cannabidivarin (CBDV) to the subject.